Based on the risk of contralateral recurrence and the risk of developing ovarian cancer several years after breast cancer, risk-reducing mastectomy (Hartmann et al., 1999) and salpingo-oophorectomy (Rebbeck et al., 2002) are recommended for BRCA1-c.211dupA carriers. This evidence concerns the gene BRCA1 and ovarian cancer.